(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 12.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Immunocore Holdings's revenue in 2024 is $249,428,000.On average, 6 Wall Street analysts forecast IMCR's revenue for 2024 to be $14,593,503,781, with the lowest IMCR revenue forecast at $13,984,646,069, and the highest IMCR revenue forecast at $15,077,212,112. On average, 6 Wall Street analysts forecast IMCR's revenue for 2025 to be $15,742,167,834, with the lowest IMCR revenue forecast at $15,152,590,700, and the highest IMCR revenue forecast at $16,421,372,251.
In 2026, IMCR is forecast to generate $17,603,764,859 in revenue, with the lowest revenue forecast at $15,461,827,245 and the highest revenue forecast at $23,490,419,030.